131 related articles for article (PubMed ID: 23796713)
21. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum.
Wheeler VC; Lebel LA; Vrbanac V; Teed A; te Riele H; MacDonald ME
Hum Mol Genet; 2003 Feb; 12(3):273-81. PubMed ID: 12554681
[TBL] [Abstract][Full Text] [Related]
22. Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.
Chen GL; Ma Q; Goswami D; Shang J; Miller GM
J Cell Mol Med; 2017 Nov; 21(11):2974-2984. PubMed ID: 28524599
[TBL] [Abstract][Full Text] [Related]
23. Cognitive training modifies disease symptoms in a mouse model of Huntington's disease.
Yhnell E; Lelos MJ; Dunnett SB; Brooks SP
Exp Neurol; 2016 Aug; 282():19-26. PubMed ID: 27163546
[TBL] [Abstract][Full Text] [Related]
24. Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2.
Bucha S; Mukhopadhyay D; Bhattacharyya NP
Biochem Biophys Res Commun; 2015 Oct; 465(4):797-802. PubMed ID: 26307536
[TBL] [Abstract][Full Text] [Related]
25. Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells.
Jen WP; Chen HM; Lin YS; Chern Y; Lee YC
Mol Neurobiol; 2020 Mar; 57(3):1688-1703. PubMed ID: 31813126
[TBL] [Abstract][Full Text] [Related]
26. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.
Trettel F; Rigamonti D; Hilditch-Maguire P; Wheeler VC; Sharp AH; Persichetti F; Cattaneo E; MacDonald ME
Hum Mol Genet; 2000 Nov; 9(19):2799-809. PubMed ID: 11092756
[TBL] [Abstract][Full Text] [Related]
27. Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington's disease knock-in striatal cell model STHdhQ111/Q111.
Ghatak S; Raha S
Biochem Biophys Res Commun; 2015 Apr; 459(3):509-14. PubMed ID: 25747711
[TBL] [Abstract][Full Text] [Related]
28. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin.
Auerbach W; Hurlbert MS; Hilditch-Maguire P; Wadghiri YZ; Wheeler VC; Cohen SI; Joyner AL; MacDonald ME; Turnbull DH
Hum Mol Genet; 2001 Oct; 10(22):2515-23. PubMed ID: 11709539
[TBL] [Abstract][Full Text] [Related]
29. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease.
Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
Free Radic Biol Med; 2019 Jan; 130():256-266. PubMed ID: 30391672
[TBL] [Abstract][Full Text] [Related]
31. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells.
Oliveira AM; Cardoso SM; Ribeiro M; Seixas RS; Silva AM; Rego AC
Neurochem Int; 2015 Dec; 91():1-12. PubMed ID: 26476055
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation of microRNA-100, -146a, and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/ Hdh(Q7) cells and human cervical carcinoma HeLa cells.
Ghose J; Bhattacharyya NP
RNA Biol; 2015; 12(4):457-77. PubMed ID: 25757558
[TBL] [Abstract][Full Text] [Related]
33. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease.
Di Pardo A; Ciaglia E; Cattaneo M; Maciag A; Montella F; Lopardo V; Ferrario A; Villa F; Madonna M; Amico E; Carrizzo A; Damato A; Pepe G; Marracino F; Auricchio A; Vecchione C; Maglione V; Puca AA
Cell Death Dis; 2020 Jul; 11(7):546. PubMed ID: 32683420
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin and cannabinoid receptors crosstalk in protection of huntingtin knock-in striatal neuronal cells in response to quinolinic acid.
Zou S; Kumar U
Neurochem Int; 2019 Oct; 129():104518. PubMed ID: 31381945
[TBL] [Abstract][Full Text] [Related]
35. Longevity-Associated Variant of BPIFB4 Confers Neuroprotection in the STHdh Cell Model of Huntington Disease.
Cattaneo M; Maciag A; Milella MS; Ciaglia E; Bruno A; Puca AA
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499641
[TBL] [Abstract][Full Text] [Related]
36. Altered microRNA expression in animal models of Huntington's disease and potential therapeutic strategies.
Martinez B; Peplow PV
Neural Regen Res; 2021 Nov; 16(11):2159-2169. PubMed ID: 33818488
[TBL] [Abstract][Full Text] [Related]
37. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice.
Fossale E; Wheeler VC; Vrbanac V; Lebel LA; Teed A; Mysore JS; Gusella JF; MacDonald ME; Persichetti F
Hum Mol Genet; 2002 Sep; 11(19):2233-41. PubMed ID: 12217951
[TBL] [Abstract][Full Text] [Related]
38. FGF9 induces neurite outgrowth upon ERK signaling in knock-in striatal Huntington's disease cells.
Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Chen CM; Yang SH
Life Sci; 2021 Feb; 267():118952. PubMed ID: 33383048
[TBL] [Abstract][Full Text] [Related]
39. Beta catenin is regulated by its subcellular distribution and mutant huntingtin status in Huntington's disease cell STHdhQ111/HdhQ111.
Ghatak S; Raha S
Biochem Biophys Res Commun; 2018 Sep; 503(1):359-364. PubMed ID: 29894684
[TBL] [Abstract][Full Text] [Related]
40. Effects of Pin1 Loss in Hdh(Q111) Knock-in Mice.
Agostoni E; Michelazzi S; Maurutto M; Carnemolla A; Ciani Y; Vatta P; Roncaglia P; Zucchelli S; Leanza G; Mantovani F; Gustincich S; Santoro C; Piazza S; Del Sal G; Persichetti F
Front Cell Neurosci; 2016; 10():110. PubMed ID: 27199664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
